(Image: Getty/Ktsimage)

Regeneron in $1bn RNAi pact with Alnylam

By Ben Hargreaves

Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.

(Image: Getty/EujarimPhotography)

US FDA vetoes Regeneron’s Eylea syringe in CRL

By Flora Southey

The US FDA has rejected Regeneron Pharmaceuticals’ prior-approval supplement for Elyea pre-filled syringe, requesting additional clinical data and manufacturing information.